Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery
NCT07332221Phase 3Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07332221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332221.